Michael Tanaka, MD

Clinical Professor

  • 1690 Citations
  • 12 h-Index
1980 …2017

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Michael Tanaka is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 1690 Citations
  • 12 h-Index
  • 20 Article

Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy

Semrad, T., Kim, E., Tanaka, M., Sands, J., Roberts, C., Burich, R. A., Li, Y., Gandara, D. R., Lara, P. N. & Mack, P., Jan 1 2017, In : Cancer Treatment and Research Communications. 10, p. 21-26 6 p.

Research output: Contribution to journalArticle

  • 9 Scopus citations

    Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

    Semrad, T., Barzi, A., Lenz, H. J., Hutchins, I. M., Kim, E., Gong, I. Y., Tanaka, M., Beckett, L. A., Holland, W., Burich, R. A., Snyder-Solis, L., Mack, P. & Lara, P. N., Aug 5 2014, In : International Journal of Clinical Oncology. 20, 3, p. 518-524 7 p.

    Research output: Contribution to journalArticle

  • 15 Scopus citations

    Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

    Ho, C., Sangha, R., Beckett, L. A., Tanaka, M., Lau, D. H., Eisen, D. B., Burich, R. A., Luciw, P. A., Khan, I., Mack, P., Gandara, D. R. & Davies, A. M., Aug 2011, In : Investigational New Drugs. 29, 4, p. 680-687 8 p.

    Research output: Contribution to journalArticle

  • 11 Scopus citations

    A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

    Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M., Lenz, H. J., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P., Lurje, G., Gandour-Edwards, R. F., Dancey, J. & Gandara, D. R., Sep 2009, In : Cancer Chemotherapy and Pharmacology. 64, 4, p. 777-783 7 p.

    Research output: Contribution to journalArticle

  • 189 Scopus citations

    Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033

    Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., Von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., Tanaka, M., Randolph Hecht, J., Heinrich, M. C., Fletcher, C. D. M., Crowley, J. J. & Borden, E. C., Feb 1 2008, In : Journal of Clinical Oncology. 26, 4, p. 626-632 7 p.

    Research output: Contribution to journalArticle

  • 745 Scopus citations